Published in final edited form as:

Org Lett. 2012 December 7; 14(23): 5824–5827. doi:10.1021/ol302575h.

Heterologous Production of 4-*O*-Demethylbarbamide, a Marine Cyanobacterial Natural Product

Eun Ji Kim[†], Jong Hyun Lee[‡], Hyukjae Choi^{§,Δ}, Alban R. Pereira[§], Yeon Hee Ban[†], Young Ji Yoo[†], Eunji Kim[†], Je Won Park[⊥], David H. Sherman^{||}, William H. Gerwick[§], and Yeo Joon Yoon[†]

William H. Gerwick: wgerwick@ucsd.edu; Yeo Joon Yoon: joonyoon@ewha.ac.kr

[†]Department of Chemistry and Nano Sciences, Ewha Womans University, Seoul 120-750

[‡]College of Pharmacy, Dongduk Women's University, Seoul 136-714, Republic of Korea

[§]Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Science, University of California San Diego, La Jolla, CA 92093

[⊥]Department of Pharmaceutical Engineering, Sun Moon University, Asan, Chungnam 336-708, Republic of Korea

^{||}Life Sciences Institute, Department of Medicinal Chemistry, Department of Chemistry, and Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109

^ΔCollege of Pharmacy, Yeungnam University, 214-1 Dae-dong, Gyeongsan 712-749, Republic of Korea

Abstract

Heterologous expression of the barbamide biosynthetic gene cluster, obtained from the marine cyanobacterium *Moorea producens*, in the terrestrial actinobacterium *Streptomyces venezuelae*, resulted in the production of a new barbamide congener 4-*O*-demethylbarbamide, demonstrating the potential of this approach for investigating the assembly and tailoring of complex marine natural products.

Marine invertebrates and bacteria are an extraordinarily rich source of novel bioactive secondary metabolites.¹ Several marine natural products and their derivatives are now used as clinical therapeutics, and many others have shown potential for the treatment of cancer, inflammation, pain, and other diseases.² However, a general impediment to the development of many of these exciting molecules is the limited quantities obtained from Nature as well as the difficulty in culturing the source organisms, including invertebrates, algae or associated symbiotic microorganisms. Moreover, total chemical synthesis of structurally complex metabolites is economically impracticable in many cases. Therefore, in order to harness the therapeutic potential of these natural product lead compounds, reliable methods must be developed for their re-supply. Cloning and heterologous expression of the biosynthetic gene clusters represents one such solution that can also facilitate the generation of insightful

Correspondence to: William H. Gerwick, wgerwick@ucsd.edu; Yeo Joon Yoon, joonyoon@ewha.ac.kr.

Supporting Information Available: Experimentals, biosynthetic details, spectroscopic data of **2**, RT-PCR, and molluscicidal assay. This material is available free of charge via the Internet at <http://pubs.acs.org>.

analog structures through metabolic engineering. To date, the majority of biosynthetic studies of marine secondary metabolites have been limited to those isolated from marine actinobacteria and cyanobacteria.³ Most genetic and enzymatic studies of cyanobacterial secondary metabolites have been conducted with the marine genus *Moorea producents* (previously classified as *Lyngbya majuscula*),⁴ a prolific producer of structurally diverse natural products⁵ including the cancer cell cytotoxin curacin A⁶ and the molluscicidal agent barbamide (**1**; Figure 1).⁷ A draft genome was recently reported for the *M. producents* 3L strain,⁸ which revealed the genetic basis for its unique spectrum of natural products. However, an inability to genetically manipulate this filamentous cyanobacterium along with its extremely slow growth rate (doubling time = 6 days or more)⁹ motivated us to develop a robust heterologous expression platform for cyanobacterial secondary metabolite gene clusters.

Although cyanobactin ribosomal peptides from cyanobacteria were heterologously produced and engineered successfully in *Escherichia coli*,¹⁰ no polyketides or hybrid polyketide-nonribosomal peptides from marine cyanobacteria have been produced in a heterologous host to date. Barbamide (**1**) attracted our attention because its biosynthetic gene cluster encoding for a NRPS/PKS (nonribosomal peptide synthetase/polyketide synthase) hybrid was the first identified from a marine cyanobacterium,¹¹ and its assembly involves several unique biochemical features such as trichlorination, a one-carbon truncation during chain extension, formation of an *E*-double bond, and thiazole ring formation (Figure 1; see the detailed biosynthetic pathway in Figure S1, Supporting Information). Currently, only the trichlorination of leucine has been biochemically characterized.¹² The 26 kb barbamide gene cluster contains twelve ORFs, designated *barA*–*barK* (GenBank accession no. AF516145).¹¹

Streptomyces spp. are known to produce an enormous range of secondary metabolites. Therefore, this genus has been used as a heterologous expression host for a variety of secondary metabolites including polyketides and nonribosomal peptides.¹³ One of the advantages of *Streptomyces* for the heterologous expression of PKS or NRPS pathways is its unique capability to accommodate these large genes compared to other heterologous hosts, such as *E. coli*.¹³ Recently, heterologous expression was applied in *Streptomyces coelicolor* M512 for the approximately 11 kb biosynthetic gene cluster of the indole alkaloid lyngbyatoxin A from *M. producents*.⁹ Despite large differences in the %GC content and codon usage between cyanobacteria and actinobacteria, two nonmodular proteins, a cytochrome P450 monooxygenase LtxB and a reverse prenyltransferase LtxC were successfully expressed, thus showing the potential of *Streptomyces* as a useful heterologous host. However, premature transcriptional termination of the *ltxA* gene product, a large bimodular NRPS, was observed and thus neither lyngbyatoxin A nor its derivatives were produced. Among *Streptomyces*, pikromycin-producing *S. venezuelae* has been developed as a promising host for the production of polyketides, hybrid polyketide-nonribosomal peptides as well as aminoglycosides due to its rapid growth and relative ease of genetic manipulation.^{14–16} Here, we demonstrate heterologous expression of the entire barbamide biosynthetic gene cluster in an engineered strain of *S. venezuelae* DHS 2001 from which the pikromycin PKS gene cluster has been deleted.¹⁷ These efforts resulted in the production of 4-*O*-demethylbarbamide (**2**; Figure 1), a new barbamide derivative that only lacks an *O*-methyl group relative to the parent structure but shows several-fold improved molluscicidal activity compared to **1**. To our knowledge, this is the first successful functional heterologous expression of a marine cyanobacterial NRPS/PKS gene cluster in a genetically amenable terrestrial host.

As a starting point, the barbamide biosynthetic genes *barA*–*barK* were cloned into a replicative *E. coli*–*Streptomyces* shuttle vector pDHS702,¹⁸ containing the *pikAI* promoter of the pikromycin PKS from cosmid PLM49¹¹ in a series of sub-cloning steps (Figure S2,

Tables S1 and S2, Supporting Information). The resulting expression plasmid pYJ1614 was designed to express the *barA–barH* genes under the control of the *pikAI* promoter and to transcribe *barI–barK* genes convergently from a native promoter in the barbamide cluster. The native intergenic regions and ribosome-binding site of each gene were maintained in this construct. The engineered plasmid was introduced into *S. venezuelae* DHS2001 to provide the *S. venezuelae* YJ348 strain. HPLC-ESI-MS/MS analysis of the organic extract of YJ348 grown on R2YE¹⁹ solid medium at 30°C for 6 days revealed a peak that was consistent with a barbamide (**1**) derivative, although **1** was not detected (Figure S3, Supporting Information). Analysis of the extracts of the cultured recombinant *S. venezuelae* YJ348 strain revealed a new peak that eluted at 42.8 min with an *m/z* 448. This product was only detected in the YJ348 strain and not from extracts obtained from *S. venezuelae* DHS2001 possessing an empty vector. The *m/z* 448 molecular ion cluster showed the characteristic isotope signature for three chlorine atoms, and the MS/MS spectrum deriving from it yielded fragment ions at *m/z* 231, 219, 188 and 134. The presence of fragments at *m/z* 219, 188 and 134 in common to those of **1**, as well as the production of a fragment at *m/z* 231 corresponding to the loss of 14 Da from the diagnostic fragment of **1** at *m/z* 245 (Figure S4, Supporting Information), suggested that it was a close structural analog of **1**. These mass differences relative to **1** suggested that the new compound was deficient in a methyl group located between the C-1 and C-4 positions. Based on the proposed barbamide biosynthetic pathway and precursor incorporation studies,²⁰ elimination of the C-1 methyl group deriving from the leucine starter unit seemed unlikely. Therefore, the new barbamide derivative detected in the extract of this engineered YJ348 strain was predicted to be 4-*O*-demethylbarbamide (**2**).

Interestingly, we found this same peak as a minor compound in partially purified *M. producens* fractions by HPLC-ESI-MS analysis, suggesting that the demethyl analog is a naturally occurring derivative of **1** (Figure S5, Supporting Information). Hence, the new analog was purified in larger scale from a *M. producens* extract by reversed-phase HPLC, and its chemical structure fully elucidated by detailed spectroscopic analyses (Figure S6 to S11, Supporting Information). The ¹H NMR spectrum of the *O*-demethyl derivative of barbamide was complicated by the presence of four interconverting isomers (**2a–2d**), present in an equilibrium ratio of *ca.* 17:7:2:1. However, 1D and 2D NMR methods were used to assign almost all shifts of the four isomers (**2a–2d**, Figure 2 and Table S3). In **2a**, HMBC correlations from H-2/H₂-3/H₂-5 to C-4 (δ_C 201.7) allowed assignment of a ketone at the C-4 position, a key point of departure from the structure of **1**. Additionally, a NOESY correlation between the NCH₃ group and H₂-5 revealed that this major compound was the *trans* amide isomer. The ¹H NMR signals of the second isomer (**2b**) were almost identical to those of **2a**, except that the chemical shift of H-7 and C-7 of **2b** were located at δ_H 5.59 and δ_C 59.8, suggesting that this was the *cis* amide conformer. Consistent with this proposal (i.e. the *cis* amide isomer with a 4-keto functionality), a NOESY correlation between the NCH₃ and H₂-5 was not observed. The NMR signals of the third isomer (**2c**) were slightly different from those of **2a**. In the ¹H NMR, H-7 of **2c** was observed at δ_H 6.27, indicating a *trans* amide isomer as found in **2a**. However, the peak for H-5 in **2c** was found as a broad singlet at δ_H 5.47 and the ¹³C NMR shift of C-5 of **2c** was located as δ_C 88.8, both of which are inconsistent with a 4-keto functionality. Furthermore, the H-5 singlet proton showed HMBC correlations with two deshielded quaternary carbons (C-4 at δ_C 174.4 and C-6 at δ_C 171.8). These data indicated that **2c** was present in the 4,5-enolic form (i.e. **2a** and **2c** are tautomers). The geometry of the Δ^{4,5} double bond was established as *Z* by observation of a NOESY correlation between H-5 and H₂-3. Finally, the chemical shifts for H-5 and C-5 of minor isomer **2d** were determined as δ_H 5.83 and δ_C 88.2, respectively, and HMBC correlations from H-5 to C-4 and C-6 again indicated the presence of a Δ^{4,5} double bond. The configuration of this olefin was determined as *Z* by observation of a NOESY correlation

between H-5 and H₂-3. However, no NOESY correlation was observed between the NCH₃ and H-5 in **2d**; combined with the chemical shifts of H-7 and C-7 at δ_{H} 6.00 and δ_{C} 58.0, respectively, these data indicated isomer **2d** possesses a *cis* amide bond. A comparison of the specific rotation of barbamide with this new barbamide analog, present as a mixture of these four isomers, allowed assignment of the absolute configuration as 2*S*, 7*S*.

Compound **2** was found to be a potent molluscicidal agent against the snail *Biomphalaria glabrata* (LD₅₀ 3.9 μM , 95% CI 2.7–5.5 μM , Figure S12, Supporting Information), and is several fold more potent than **1** itself (revised LD₁₀₀ 22 μM).⁷ Indeed, we had long recognized that there was a more potent molluscicide in the extract of this cyanobacterium, but had been unable to complete its structure elucidation as **2** due to the small quantity and multiple isomers in solution.

It is plausible that **2** is a biosynthetic congener of **1**, which results from skipping of the BarF-catalyzed *O*-methylation reaction (Figures 1 and S1, Supporting Information). However, it is at present unclear why **2** is generated as the sole product in the heterologous host. Semi-quantitative RT-PCR analysis of the transcript levels in the engineered YJ348 strain demonstrated that most of the *bar* genes are transcribed, including *barF* that encodes for the *O*-methyltransferase (Figure S13, Supporting Information). Therefore, it is possible that the *barF* transcript is unstable in *S. venezuelae* and fails to be translated. Alternatively, other gene product(s) located outside of the barbamide gene cluster might facilitate the unfavourable energetics involved in forming the *E* enol substrate which appears to be required for the *O*-methyl transfer reaction to form **1**. The detection of *barJ* transcripts suggests that the native *Moorea* promoter can be recognized in *Streptomyces*, as previously reported,⁹ although its expression level appears to be lower as compared to genes transcribed from the *Streptomyces* promoter. Therefore, placement of a *Streptomyces* promoter in front of the *barF*–*barK* operon could increase production of **2**. However, truly significant enhancement of production would not be expected because even the expression levels of those cyanobacterial genes driven by the *pikAI* promoter were low compared to *Streptomyces* PKS genes heterologously expressed in *S. venezuelae*,¹⁷ probably due to codon usage bias between cyanobacteria and actinobacteria.

In the absence of a gene disruption system for *M. producens*, identification of the barbamide gene cluster was supported by ATP-PP_i exchange assay results using the BarE NRPS adenylation domain as well as the halogenase activity of both BarB1 and BarB2 using recombinant enzymes expressed in *E. coli*.^{8,9} The production of **2** by heterologous expression of the 26 kb barbamide gene cluster (*barA*–*barK*) unequivocally confirms the identity of this gene cluster. In addition, our results demonstrate that the *barA*–*barK* genes constitute the minimal gene set required for formation of **2**, which includes the unusual one-carbon truncation. However, significant challenges remain in the heterologous production of **2** in *S. venezuelae*, most dramatically the very low production yields (less than 1 $\mu\text{g/L}$) which may be due to suboptimal codon usage in the cyanobacteria DNA compared to the ‘high %GC content’ actinobacteria. Our previous studies demonstrated that heterologous expression of tylosin PKS genes derived from *S. fradiae* produced approximately 0.5 mg/L of ty lactone using the same host and vector system employed in this study.¹⁷ However, heterologous expression of epothilone NRPS-PKS genes obtained from the myxobacterium *Sorangium cellulosum* produced very low levels of epothilone (less than 1 $\mu\text{g/L}$).¹⁵ Synthesis and expression of codon-optimized *bar* biosynthetic genes corresponding to the *S. venezuelae* codon bias would likely improve production of **2**, as observed for production of plant-derived phenylpropanoids in *S. venezuelae*.²¹

The results presented herein provide an important precedent and approach for the biosynthetic study of marine natural products derived from genetically intractable

organisms, such as sheath-containing filamentous cyanobacteria. In the current work, we demonstrated heterologous production and identification of a new barbamide derivative **2**, which had not been previously isolated from the natural producer. This new compound is several fold more potent than **1** as a molluscicide, and given its lack of other toxicities,⁷ may be a superb candidate for treating snail-infested waterways which pose health risks for human populations. Moreover, we report here the first functional heterologous expression of a complete marine cyanobacterial NRPS/PKS gene cluster using a readily manipulable antibiotic-producing *Streptomyces* species, suggesting new opportunities for the large-scale production of valuable marine natural products. Continued advances using cloning-independent next-generation sequencing-based metagenomic approaches²² will certainly provide numerous biosynthetic gene clusters from unculturable symbionts or environmental metagenomic DNA. Heterologous gene expression technologies will thus play a critical role in understanding their products and advancing their utility in drug discovery programs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Research Foundation (NRF) grant funded by the Korea government (MEST) (20110018617 and 20100001487), the Intelligent Synthetic Biology Center of Global Frontier Project funded by MEST (20110031961), the Marine and Extreme Genome Research Center Program of the Ministry of Land, Transportation and Maritime Affairs, Republic of Korea, and the National Institutes of Health grant CA108874 (D.H.S and W.H.G). We thank the Korea Basic Science Institute for recording 900 MHz NMR spectra.

References

- Salomon C, Magarvey N, Sherman D. Nat Prod Rep. 2004; 21:105. [PubMed: 15039838]
- Gerwick W, Moore B. Chem Biol. 2012; 19:85. [PubMed: 22284357]
- Lane A, Moore B. Nat Prod Rep. 2011; 28:411. [PubMed: 21170424]
- Engene N, Rottacker E, Kastovsky J, Byrum T, Choi H, Ellisman M, Komarek J, Gerwick W. Int J Syst Evol Microbiol. 2012; 62:1171. [PubMed: 21724952]
- Jones A, Monroe E, Eisman E, Gerwick L, Sherman D, Gerwick W. Nat Prod Rep. 2010; 27:1048. [PubMed: 20442916]
- Gerwick W, Proteau P, Nagle D, Hamel E, Blokhin A, Slate D. J Org Chem. 1994; 59:1243.
- Orjala J, Gerwick W. J Nat Prod. 1996; 59:427. [PubMed: 8699186]
- Jones A, Monroe E, Podell S, Hess W, Klages S, Esquenazi E, Niessen S, Hoover H, Rothmann M, Lasken R, Yates J, Reinhardt R, Kube M, Burkart M, Allen E, Dorrestein P, Gerwick W, Gerwick L. Proc Natl Acad Sci USA. 2011; 108:8815. [PubMed: 21555588]
- Jones A, Otilie S, Eustaquio A, Edwards D, Gerwick L, Moore B, Gerwick W. FEBS J. 2012; 279:1243. [PubMed: 22314229]
- (a) Schmidt E, Nelson J, Rasko D, Sudek S, Eisen J, Haygood M, Ravel J. Proc Natl Acad Sci U S A. 2005; 102:7315. [PubMed: 15883371] (b) Tianero M, Donia M, Young T, Schultz P, Schmidt E. J Am Chem Soc. 2012; 134:418. [PubMed: 22107593]
- Chang Z, Flatt P, Gerwick W, Nguyen V, Willis C, Sherman D. Gene. 2002; 296:235. [PubMed: 12383521]
- Galoni D, Vaillancourt F, Walsh C. J Am Chem Soc. 2006; 128:3900. [PubMed: 16551084]
- Zhang H, Boghigian B, Armando J, Pfeifer B. Nat Prod Rep. 2011; 28:125. [PubMed: 21060956]
- Park S, Han A, Ban Y, Yoo Y, Kim E, Yoon Y. Appl Microbiol Biotechnol. 2010; 85:1227. [PubMed: 19902203]
- Park S, Park J, Jung W, Han A, Ban Y, Kim E, Sohng J, Sim S, Yoon Y. Appl Microbiol Biotechnol. 2008; 81:109. [PubMed: 18769916]

16. Park J, Park S, Nepal K, Han A, Ban Y, Yoo Y, Kim E, Kim E, Kim D, Sohng J, Yoon Y. *Nat Chem Biol.* 2011; 7:843. [PubMed: 21983602]
17. Jung W, Lee S, Hong J, Park S, Jeong S, Han A, Sohng J, Kim B, Choi C, Sherman D, Yoon Y. *Appl Microbiol Biotechnol.* 2006; 72:763. [PubMed: 16493552]
18. Xue Y, Sherman D. *Metab Eng.* 2001; 3:15. [PubMed: 11162229]
19. Kieser, T.; Bibb, M.; Buttner, M.; Chater, K.; Hopwood, D. *Practical Streptomyces Genetics.* John Innes Centre; Norwich, England: 2000.
20. (a) Flatt P, O'Connell S, McPhail K, Zeller G, Willis C, Sherman D, Gerwick W. *J Nat Prod.* 2006; 69:938. [PubMed: 16792414] (b) Sitachitta N, Rossi J, Roberts M, Gerwick W, Fletcher M, Willis C. *J Am Chem Soc.* 1998; 120:7131.
21. Park S, Yoon J, Paik J, Park J, Jung W, Ban Y, Kim E, Yoo Y, Han A, Yoon Y. *J Biotechnol.* 2009; 141:181. [PubMed: 19433224]
22. Rath C, Janto B, Earl J, Ahmed A, Hu F, Hiller L, Dahlgren M, Kreft R, Yu F, Wolff J, Kweon H, Christiansen M, Hakansson K, Williams R, Ehrlich G, Sherman D. *ACS Chem Biol.* 2011; 6:1244. [PubMed: 21875091]

Figure 1. Barbamide gene cluster and the proposed biosynthetic pathways for 4-*O*-demethylbarbamide (2) and barbamide (1).¹¹ A, adenylation domain; ACP, acyl carrier protein; AT, acyltransferase domain; C, condensation domain; Cy, cyclization domain; KS, ketosynthase domain; MT, methyltransferase domain; PCP, peptidyl carrier protein; TE, thioesterase domain.

Figure 2. Simultaneous structure elucidation of four isomers of 4-*O*-demethylbarbamide (**2a–2d**) based on key COSY, HMBC and NOESY correlations.